2019年4月11日 · A rapid confirmation of genetic diagnosis is mandatory and should be performed, if possible, on bone marrow (BM) samples.

2023年6月26日 · Acute promyelocytic leukemia is a distinguished subset of acute myeloid leukemia which is characterized by fusion gene transcript PML-RAR-alpha and high cure rates with treatment.

2021年6月30日 · Acute promyelocytic leukemia (APL), a subtype of acute myeloid leukemia (AML), accounts for 10–15% of newly diagnosed AML cases. Approximately 800 patients are...

2018年7月26日 · Risk-adapted therapy allowed achieving remarkable cure rates in an international trial on childhood APL. Reduction of the anthracycline cumulative dose coupled with ATRA extended use does not compromise the outcome of children with APL. Pediatric acute promyelocytic leukemia (APL) can be cured with all- trans retinoic acid (ATRA) and anthracycline.

2009年12月10日 · Acute promyelocytic leukemia is the first malignant disease highly curable with targeted therapy directed at a unique molecular abnormality. The characteristic bleeding diathesis is the most notorious manifestation of the disease, which historically has accounted for a high mortality rate during induction.

Acute promyelocytic leukemia is a distinct subtype of acute myeloid leukemia. The disease is characterized by a chromosomal abnormality involving translocation between chromosomes 15 and 17. Current therapy has advanced to include agents such as all- trans retinoic acid and arsenic trioxide, which have improved remission and survival rates.

2024年5月21日 · What is APML? Acute promyelocytic leukaemia (APML) is a rare sub-type of acute myeloid leukaemia (AML) and is sometimes referred to as AML M31. APML accounts for only 10% of all AML diagnoses. In APML, immature abnormal neutrophils (a type of white blood cell) known as promyelocytes accumulate in the bone marrow. These immature cells are unable ...

2010年1月1日 · Bone marrow (BM) and/or peripheral blood (PB) smears from 349 patients in whom the diagnosis of APL was considered were assessed with the anti-PML antibody using immunofluorescence. The study group included 199 patients with confirmed APL and 150 with other conditions.

After the initial therapeutic success reported in 1973 using an anthracycline (daunorubicin), 1 the management and outcome of acute promyelocytic leukemia (APL) has been revolutionized by the introduction of all- trans retinoic acid (ATRA; tretinoin) and arsenic trioxide (ATO) in 1988 2 and 1996, 3 respectively.

Acute promyelocytic anaemia is characterized by the presence of atypical promyelocytes and a t (15;17) translocation, resulting in a PML-RARA fusion. It is often associated with pancytopenia and disseminated intravascular coagulation. Both hypergranlar and hypogranular variants exist.